

Subject index

Volume 54 (2002)

Acyclic purine; Antiviral; Cowpox virus; Orthopox virus; Cidofovir **54**, 113

Acyclovir; Herpes simplex virus type 1; Thymidine kinase; Drug-resistance; Antivirals; Thymidine kinase expressing cells **54**, 163

Aerosol; Cowpox virus; Orthopoxvirus; Smallpox; Cidofovir; HPMPC; Cyclic HPMPC; Antiviral therapy **54**, 129

Animal models; Antiviral activity; Human hepatitis B virus; Transgenic mice **54**, 69

Anti-HIV activity; Early pregnancy associated protein; Pregnancy; gp120–CD4 interaction **54**, 47

Antiviral activity; Animal models; Human hepatitis B virus; Transgenic mice **54**, 69

Antiviral activity; Herpesviruses; DNA polymerases; Dihydroquinoline; PNU-183792 **54**, 19

Antiviral; Cowpox virus; Orthopox virus; Acyclic purine; Cidofovir **54**, 113

Antiviral; Lymphocyte; Liposome; HIV; SPC3 **54**, 175

Antivirals; Herpes simplex virus type 1; Thymidine kinase; Drug-resistance; Acyclovir; Thymidine kinase expressing cells **54**, 163

Antiviral therapy; Cowpox virus; Orthopoxvirus; Smallpox; Cidofovir; HPMPC; Cyclic HPMPC; Aerosol **54**, 129

Antiviral therapy; Filovirus; Ebola virus; Marburg virus; S-adenosyl-L-homocysteine hydrolase; Interferon- α **54**, 1

Apoptosis; Liposomal povidone-iodine; Aqueous povidone-iodine; Virucidal activity; Cytotoxicity; Membrane toxicity **54**, 89

Aqueous povidone-iodine; Liposomal povidone-iodine; Virucidal activity; Cytotoxicity; Membrane toxicity; Apoptosis **54**, 89

bis-Tetrahydrofuran; Human immunodeficiency virus; Protease inhibitor; Structure-based design **54**, 29

Cidofovir; Antiviral; Cowpox virus; Orthopox virus; Acyclic purine **54**, 113

Cidofovir; Cowpox virus; Orthopoxvirus; Smallpox; HPMPC; Cyclic HPMPC; Aerosol; Antiviral therapy **54**, 129

Clade A; Vaccine; HIV-1; Virus-like particles **54**, 189

Cowpox virus; Antiviral; Orthopox virus; Acyclic purine; Cidofovir **54**, 113

Cowpox virus; Orthopoxvirus; Smallpox; Cidofovir; HPMPC; Cyclic HPMPC; Aerosol; Antiviral therapy **54**, 129

Cyclic HPMPC; Cowpox virus; Orthopoxvirus; Smallpox; Cidofovir; HPMPC; Aerosol; Antiviral therapy **54**, 129

Cyclodextrins; Human cytomegalovirus; Drug carrier; Ganciclovir-resistance **54**, 121

Cytomegalovirus; Ganciclovir resistance; UL97; Recombinant vaccinia virus **54**, 59

Cytotoxicity; Liposomal povidone-iodine; Aqueous povidone-iodine; Virucidal activity; Membrane toxicity; Apoptosis **54**, 89

Cytotoxicity; Tenofovir; Nucleoside reverse transcriptase inhibitors (NRTI); Hematopoiesis **54**, 37

Dihydroquinoline; Herpesviruses; DNA polymerases; Antiviral activity; PNU-183792 **54**, 19

DNA polymerases; Herpesviruses; Antiviral activity; Dihydroquinoline; PNU-183792 **54**, 19

Drug carrier; Human cytomegalovirus; Cyclodextrins; Ganciclovir-resistance **54**, 121

Drug-resistance; Herpes simplex virus type 1; Thymidine kinase; Acyclovir; Antivirals; Thymidine kinase expressing cells **54**, 163

Early pregnancy associated protein; Anti-HIV activity; Pregnancy; gp120–CD4 interaction **54**, 47

Ebola virus; Filovirus; Marburg virus; Antiviral therapy; S-adenosyl-L-homocysteine hydrolase; Interferon- α **54**, 1

Ferret; Influenza; Transmission; Neuraminidase; Resistance **54**, 99

Filovirus; Ebola virus; Marburg virus; Antiviral therapy; S-adenosyl-L-homocysteine hydrolase; Interferon- α **54**, 1

Ganciclovir resistance; Cytomegalovirus; UL97; Recombinant vaccinia virus **54**, 59

Ganciclovir-resistance; Human cytomegalovirus; Drug carrier; Cyclodextrins **54**, 121

gp120–CD4 interaction; Early pregnancy associated protein; Anti-HIV activity; Pregnancy **54**, 47

Hematopoiesis; Tenofovir; Nucleoside reverse transcriptase inhibitors (NRTI); Cytotoxicity **54**, 37

Herpes simplex virus type 1; Thymidine kinase; Drug-resistance; Acyclovir; Antivirals; Thymidine kinase expressing cells **54**, 163

Herpesviruses; DNA polymerases; Antiviral activity; Dihydroquinoline; PNU-183792 **54**, 19

High throughput screening (HTS); Human immunodeficiency virus (HIV); Rev, Rev response element (RRE); Protein–RNA interaction **54**, 149

HIV; Lymphocyte; Liposome; Antiviral; SPC3 **54**, 175

HIV-1; Vaccine; Clade A; Virus-like particles **54**, 189

HPMPC; Cowpox virus; Orthopoxvirus; Smallpox; Cidofovir; Cyclic HPMPC; Aerosol; Antiviral therapy **54**, 129

Human cytomegalovirus; Drug carrier; Cyclodextrins; Ganciclovir-resistance **54**, 121

Human hepatitis B virus; Antiviral activity; Animal models; Transgenic mice **54**, 69

Human immunodeficiency virus (HIV); Rev, Rev response element (RRE); Protein–RNA interaction; High throughput screening (HTS) **54**, 149

Human immunodeficiency virus; Protease inhibitor; bis-Tetrahydrofuran; Structure-based design **54**, 29

Influenza A; Influenza B; Inhibitors; Virus **54**, 143

Influenza B; Inhibitors; Virus; Influenza A **54**, 143

Influenza; Ferret; Transmission; Neuraminidase; Resistance **54**, 99

Influenza; Tamiflu; Oseltamivir phosphate; Neuraminidase; Resistance **54**, 79

Inhibitors; Influenza B; Virus; Influenza A **54**, 143

Interferon- α ; Filovirus; Ebola virus; Marburg virus; Antiviral therapy; S-adenosyl-L-homocysteine hydrolase **54**, 1

Liposomal povidone-iodine; Aqueous povidone-iodine; Virucidal activity; Cytotoxicity; Membrane toxicity; Apoptosis **54**, 89

Liposome; Lymphocyte; HIV; Antiviral; SPC3 **54**, 175

Lymphocyte; Liposome; HIV; Antiviral; SPC3 **54**, 175

Marburg virus; Filovirus; Ebola virus; Antiviral therapy; S-adenosyl-L-homocysteine hydrolase; Interferon- α **54**, 1

Membrane toxicity; Liposomal povidone-iodine; Aqueous povidone-iodine; Virucidal activity; Cytotoxicity; Apoptosis **54**, 89

Neuraminidase; Influenza; Ferret; Transmission; Resistance **54**, 99

Neuraminidase; Tamiflu; Oseltamivir phosphate; Influenza; Resistance **54**, 79

Nucleoside reverse transcriptase inhibitors (NRTI); Tenofovir; Cytotoxicity; Hematopoiesis **54**, 37

Orthopox virus; Antiviral; Cowpox virus; Acyclic purine; Cidofovir **54**, 113

Orthopoxvirus; Cowpox virus; Smallpox; Cidofovir; HPMPC; Cyclic HPMPC; Aerosol; Antiviral therapy **54**, 129

Oseltamivir phosphate; Tamiflu; Influenza; Neuraminidase; Resistance **54**, 79

PNU-183792; Herpesviruses; DNA polymerases; Antiviral activity; Dihydroquinoline **54**, 19

Pregnancy; Early pregnancy associated protein; Anti-HIV activity; gp120–CD4 interaction **54**, 47

Protease inhibitor; Human immunodeficiency virus; bis-Tetrahydrofuran; Structure-based design **54**, 29

Protein–RNA interaction; Human immunodeficiency virus (HIV); Rev, Rev response element (RRE); High throughput screening (HTS) **54**, 149

Recombinant vaccinia virus; Ganciclovir resistance; Cytomegalovirus; UL97 **54**, 59

Resistance; Influenza; Ferret; Transmission; Neuraminidase **54**, 99

Resistance; Tamiflu; Oseltamivir phosphate; Influenza; Neuraminidase **54**, 79

Rev, Rev response element (RRE); Human immunodeficiency virus (HIV); Protein–RNA interaction; High throughput screening (HTS) **54**, 149

S-adenosyl-L-homocysteine hydrolase; Filovirus; Ebola virus; Marburg virus; Antiviral therapy; Interferon- α **54**, 1

Smallpox; Cowpox virus; Orthopoxvirus; Cidofovir; HPMPC; Cyclic HPMPC; Aerosol; Antiviral therapy **54**, 129

SPC3; Lymphocyte; Liposome; HIV; Antiviral **54**, 175

Structure-based design; Human immunodeficiency virus; Protease inhibitor; bis-Tetrahydrofuran **54**, 29

Tamiflu; Oseltamivir phosphate; Influenza; Neuraminidase; Resistance **54**, 79

Tenofovir; Nucleoside reverse transcriptase inhibitors (NRTI); Cytotoxicity; Hematopoiesis **54**, 37

Thymidine kinase expressing cells; Herpes simplex virus type 1; Thymidine kinase; Drug-resistance; Acyclovir; Antivirals **54**, 163

Thymidine kinase; Herpes simplex virus type 1; Drug-resistance; Acyclovir; Antivirals; Thymidine kinase expressing cells **54**, 163

Transgenic mice; Antiviral activity; Animal models; Human hepatitis B virus **54**, 69

Transmission; Influenza; Ferret; Neuraminidase; Resistance **54**, 99

UL97; Ganciclovir resistance; Cytomegalovirus; Recombinant vaccinia virus **54**, 59

Vaccine; HIV-1; Clade A; Virus-like particles **54**, 189

Virucidal activity; Liposomal povidone-iodine; Aqueous povidone-iodine; Cytotoxicity; Membrane toxicity; Apoptosis **54**, 89

Virus; Influenza B; Inhibitors; Influenza A **54**, 143

Virus-like particles; Vaccine; HIV-1; Clade A **54**, 189